A phase II, open-label, multicenter study of GW572016 in patients with trastuzumab-refractory metastatic breast cancer

Kim T. Blackwell(University of Iowa), M. S. Berger(Duke University), M. J. Sorensen(GlaxoSmithKline (United States)), Janet Maleski(GlaxoSmithKline (United States)), P. Kelly Marcom(Duke University), Eli Kaplan(Tel Aviv University), Sandra Franco(Clínica Santa María)
Journal of Clinical Oncology
July 15, 2004
10.1200/jco.2004.22.14_suppl.3006
Cited by 44

Related Papers

Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2018|1.6k
Selective Ablation of Acute Myeloid Leukemia Using Antibody-Targeted Chemotherapy: A Phase I Study of an Anti-CD33 Calicheamicin Immunoconjugate
|Blood|1999|456
Selective Ablation of Acute Myeloid Leukemia Using Antibody-Targeted Chemotherapy: A Phase I Study of an Anti-CD33 Calicheamicin Immunoconjugate
|Blood|1999|439
Characterization of A1, a novel hemopoietic-specific early-response gene with sequence similarity to <i>bcl-2</i> .
|The Journal of Immunology|1993|336
Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2016|315